Artificial Intelligence

A new initiative is tackling the fear and distrust that costs patients their health and the system trillions. Is 'cognitive safety' healthcare's next frontier?

Founder Chuck Cohn pours millions more into his ed-tech firm, a bold move that signals deep confidence despite a slumping stock and cautious analysts.

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

William Healey, a 25-year veteran, takes the helm as IAAO's 2026 President, guiding the future of global property valuation amid technological change.

With surging revenue for its cholesterol drugs and new guideline backing, Esperion outlines its strategy for profitability and pipeline expansion.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

A new partnership aims to accelerate driver safety tech in next-gen vehicles, merging AI monitoring with a fortress-like operating system.

With 35 years at the company, new CEO John Baylouny plans to accelerate R&D and expand into new markets, building on a period of strong growth.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

Routeware appoints proven tech leaders Jeremy Collins and Ray Greer to drive its next growth phase, focusing on platform modernization and market leadership.

With blockbuster sales from VYJUVEK, Krystal Biotech heads to J.P. Morgan with investors eager for news on its global growth and ambitious pipeline.

A new partnership between etherWhere and AsiaRF promises ultra-low power, high-precision location tracking for everything from police cameras to Wi-Fi 7.

A tiny implant stimulating the vagus nerve offers new hope for severe RA. A landmark study now validates this bioelectric therapy for patients out of options.

Off The Hook's new luxury division leverages AI and an integrated model to secure ~$100M in listings and close 22 deals in its explosive first quarter.

Weight Watchers now offers the new Wegovy pill, a needle-free option, betting its future on combining powerful GLP-1 drugs with its classic support.

With deep institutional and private sector tech experience, new CEO Andrew Bercich is tasked with guiding the U.S. workforce system through a pivotal era.

Amid a capacity crisis, a new model blending AI with human oversight gains traction, promising efficiency without sacrificing the crucial element of patient care.

China's ETF market had a record 2025, fueled by AI breakthroughs and state support. A look at the boom, the leaders, and the risks ahead.

Circle Pharma will unveil its pipeline of novel oral macrocycle drugs targeting elusive cancer drivers at the influential J.P. Morgan Healthcare Conference.

With record Q3 earnings and strong analyst ratings, Red Violet is set to present its identity intelligence growth strategy at the prestigious Needham conference.